HIV PreventionNCT07829250
Pharmacies in HIV Prevention: Fellowship, Fundamentals, and Sustainable Finances
A study testing Virtual Community of Practice in people with HIV Prevention, run by University of Washington.
Trial summary
Quantify the impact of an online Virtual Community of Practice (VCoP) to increase pharmacist knowledge and accelerate provision of pre-exposure prophylaxis (PrEP) for HIV prevention. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV Prevention
- What is being tested?
- Virtual Community of Practice
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2026to 28 Feb 2031
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pharmacists or pharmacy staff working at pharmacy in U.S.
- Pharmacy is not currently providing PrEP
Who cannot join
- Any potential participants unable to fully complete the proposed study activities due to health or other concerns will be excluded in the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Quantify the impact of an online Virtual Community of Practice (VCoP) to increase pharmacist knowledge and accelerate provision of pre-exposure prophylaxis (PrEP) for HIV prevention.
Read the detailed description
Communities of practice unite individuals and provide opportunity to share knowledge, develop skills, and reduce isolation. We will conduct a Type 3 hybrid effectiveness-implementation trial to evaluate implementation outcomes (e.g. acceptability, feasibility, and adoption) and effectiveness (e.g. number of PrEP initiations). The primary outcome will compare time to first PrEP prescription among 180 pharmacies randomized to an enhanced standard of care arm plus or minus VCoP access. We hypothesize that pharmacies with VCoP access will create their programs and provide their first oral PrEP prescriptions in less time than pharmacies without VCoP access.
- Conditions
- HIV Prevention
- Being tested
- Virtual Community of Practice, Enhanced Standard of Care
- Keywords
- PrEP, Pharmacy, HIV prevention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Community of PracticeBehavioural
Healthcare communities of practice (CoPs) are becoming increasingly popular. CoPs unite individuals with common interests and provide opportunity to collaboratively learn and develop skills to improve professional practice, and reduce isolation. CoPs can play a role when educational needs cannot be satisfied by traditional methods. With advances in technology and the COVID-19 pandemic, virtual communities of practice (VCoPs) have spread across the globe.
One of the primary benefits of online VCoPs is expanded potential for professional development and remote networking. VCoP members can use asynchronous communication to develop relationships and learn from peers who have experience with laws, policies, insurance companies and other healthcare institutions across the U.S. This education and peer support provided by VCoPs could be particularly beneficial for pharmacists in rural areas or in EHE jurisdictions without access to similar resources as academic or urban pharmacists.
Enhanced Standard of CareBehavioural
A self-guided business and program planning. This arm will be sent a syllabus introducing them to the six-month business and program plan. Assignments will be delivered every other week, focusing on clinical, epidemiological, and business related educational tasks to be completed to prepare pharmacist to offer PrEP. The study team will be available for email assistance.
| Study group | Role | What they receive |
|---|---|---|
| Enhanced Standard of Care | Active comparator | This arm will be sent a syllabus introducing them to the six-month business and program plan. Assignments will be delivered every other week, focusing on clinical, epidemiological, and business related educational tasks to be completed to prepare pharmacist to offer PrEP. The study team will be available for email assistance. Receives: Behavioral: Enhanced Standard of Care |
| Virtual Community of Practice Arm | Experimental | VCoP arm participants will have the same assignments as described in the enhanced SoC arm. Additionally, pharmacists and staff randomized to gain VCoP access will be invited by the research coordinator to the VCoP. The VCoP will include the research team and pharmacists with experience in PrEP provision to provide education and peer support. Receives: Behavioral: Virtual Community of Practice |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first PrEP prescription
Time to first PrEP prescription by participating pharmacists as self-reported.
Measured: for 2 years from participant enrollment.
Secondary outcomes (3)
PrEP Clinics Started
Total number of PrEP Clinics started by participants
Measured: within 2 years of participant enrollment
Total numbers of PrEP prescriptions initiated
Total numbers of PrEP prescriptions initiated by participants
Measured: within 2 years of participant enrollment
characteristics of PrEP patients
characteristics of PrEP patients
Measured: 2 years post-enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion28 Feb 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV PreventionStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Joanne Stekler, MD MPH, University of Washington
- Investigators
- Joanne Stekler, MD, MPH, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07829250
- Sponsor's protocol ID
- STUDY00023020
- Other IDs
- 1R01MH140473
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided